Mark R. Etherton

Oveporexton for Narcolepsy Type 1 — Results from Two Phase 3 Trials

BACKGROUND: Narcolepsy type 1 is characterized by excessive daytime sleepiness, cataplexy, disrupted sleep, sleep paralysis, and hypnagogic or hypnopompic hallucinations. Oveporexton (TAK-861), an oral orexin receptor 2-selective agonist, reduced symptoms of narcolepsy type 1 in...